Clinical Trial

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervous system.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2017-08-30; most recent amendment 2026-02-25.
Status change: Not Yet Recruiting → Recruiting 2017-10-31
Trial Details
NCT Number NCT03270059
Lead Sponsor OHSU Knight Cancer Institute
Collaborators: Celgene Corporation, Oregon Health and Science University
Conditions Central Nervous System Neoplasm, Cranial Nerve Disorder, Metastatic Malignant Neoplasm in the Brain
Enrollment 150 participants
Start Date 2017-10-06
Primary Completion 2027-12-15 (estimated)
Study Completion 2028-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-27